Vanda Pharmaceuticals Inc. (VNDA), a global biopharmaceutical company with a robust commercial portfolio of 4 approved drugs, faces a near-term regulatory catalyst expected next month, which could have a significant impact on its long-term growth prospects.
The company's investigational drug Bysanti, proposed for the treatment of adults with acute bipolar I disorder and schizophrenia, is under FDA review with a decision expected on February 21, 2026. Bysanti belongs to the class of atypical antipsychotic drugs and is designed to interact with a host of neurotransmitter receptors in the brain, including the alpha-adrenergic receptor, serotonin receptors and dopamine receptors to achieve its therapeutic effect.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.